New treatment that improves control of diabetes at mealtimes now available in UK

A new, fast-acting mealtime insulin for adults living with type 1 or type 2 diabetes has been launched in the UK. Fast-acting insulin aspart (Fiasp) is a formulation that more closely matches the natural physiological insulin response of a person without diabetes, after meals, compared with the rapid-acting insulin, insulin aspart (NovoRapid). Fast-acting insulin aspart will be made available to the NHS at no additional cost versus conventional insulin aspart and may help patients tighten the control of their blood sugar levels after meals. Professor David Russell-Jones, Consultant Physician at the Royal Surrey County Hospital, and Professor of Diabetes and Endocrinology at the